Riskpilot← Back to searchSign inGet full accessARCTIC BIOPHARMA AS
ASActiveOrg 823954492Industrivegen 42, 6155 ØrstaWholesale of pharmaceutical and medical goods · NACE 4646Est. 20190 employees
Revenue 2024
NOK 0
EBITDA margin
—
+16% vs 2023
Equity ratio
-1549.8%
Financial strength
Net profit 2024
NOK -14K
+15% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -14K | +16% |
| Net profit | NOK -14K | +15% |
| Total assets | NOK 3K | +166% |
| Equity | NOK -40K | -54% |
| Employees | 0 | — |
Legal name
ARCTIC BIOPHARMA AS
Org number
823954492
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
27. november 2019
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Salg og utvikling av biomedisinske produkter og tjenester. Formålet kan fremmes ved deltakelse i eller samarbeid med andre foretak i inn- og utland være et investeringsselskap, herunder investeringer i aksjer og verdipapirer i andre selskaper og annet som står i naturlig forbindelse med dette.
Address
Industrivegen 42, 6155 Ørsta
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −6 | −11 | −14 | −16 | −14 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −6 | −11 | −14 | −16 | −14 |
| Net financials | 0 | 0 | −0 | −0 | −0 |
| Profit before tax | −6 | −11 | −14 | −16 | −14 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −6 | −11 | −14 | −16 | −14 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 19 | 17 | 3 | 1 | 3 |
| Equity | 16 | 4 | −10 | −26 | −40 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 | 13 | 13 | 27 | 42 |
| Total debt | 3 | 13 | 13 | 27 | 42 |
EBITDA margin
-1353000.0%
This company
15.8%
Market median
-8563391% vs market
20202024
Equity ratio
-1549.8%
This company
38.2%
Market median
-4157% vs market
20202024
Return on equity
-1384000.0%
This company
18.4%
Market median
-7521839% vs market
20202024
Net profit margin
-1384000.0%
This company
8.1%
Market median
-17086520% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.06×
This company
0.62×
Market median
-71% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2019-10-04 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
DM Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2022 | |
| Former (1) | ||
| Chairman | 2019 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Bakk Invest As
ARCTIC BIOPHARMA AS Board members of ARCTIC BIOPHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Danielle Marie Glenn Veierod | Chief Executive Officer | 0 companies |
| Harald Nordal | Chairman | 0 companies |
| Ole Arne Eiksund | Chairman | 0 companies |